No, Letermovir Cannot Replace Acyclovir for HSV Prophylaxis Post-HSCT
Letermovir lacks activity against herpes simplex virus (HSV) and therefore cannot substitute for acyclovir in HSV prophylaxis after hematopoietic stem cell transplantation. Patients receiving letermovir for CMV prophylaxis must continue concurrent acyclovir (or valacyclovir/famciclovir) for HSV and VZV coverage 1.
Critical Distinction in Antiviral Spectrum
The 2024 NCCN Guidelines explicitly state that additional prophylaxis with acyclovir is required in patients receiving CMV prophylaxis with letermovir as this agent lacks activity against HSV 1. This is fundamentally different from ganciclovir or foscarnet, which provide dual coverage for both CMV and HSV, eliminating the need for additional acyclovir 1.
The FDA drug label confirms letermovir's mechanism targets the CMV DNA terminase complex (pUL51, pUL56, and pUL89), which is CMV-specific 2. Drug interaction studies show no antagonism when letermovir is combined with acyclovir, supporting their concurrent use 2.
Algorithmic Approach to Antiviral Prophylaxis Post-HSCT
For CMV-Seropositive Allogeneic HSCT Recipients:
Weeks 0-14 (or longer):
- Letermovir 480 mg daily (240 mg if on cyclosporine) for CMV prophylaxis 1
- PLUS acyclovir/valacyclovir/famciclovir for HSV/VZV prophylaxis 1
Weeks 14-52:
- Continue acyclovir/valacyclovir for VZV prophylaxis (at least 1 year post-transplant) 1
- Extend if ongoing immunosuppression or GVHD 1
Why Both Agents Are Necessary:
HSV reactivation occurs in 60-80% of seropositive HSCT recipients without prophylaxis, primarily in the first month but can occur during any period of intense immunosuppression 1
VZV reactivation affects approximately 30% of allogeneic HSCT recipients without prophylaxis, with risk extending through the first year 1
Acyclovir prophylaxis (1-2 months to 1 year post-HSCT) significantly reduces VZV disease from 26% to 5% and simultaneously prevents HSV reactivations 1
Common Pitfall to Avoid
Do not discontinue acyclovir when initiating letermovir. This is a critical error that leaves patients vulnerable to HSV and VZV reactivation. The NCCN Guidelines emphasize this requirement across multiple sections 1, and recent reviews confirm that HSV/VZV prophylaxis remains a cornerstone of prevention even with newer CMV-targeted therapies 3.
Clinical Context
While letermovir represents a significant advance in CMV prophylaxis—reducing clinically significant CMV infection from 61% to 38% in phase 3 trials 1—it addresses only one component of herpesvirus prevention. The antiviral spectrum is fundamentally different from nucleoside analogues like acyclovir, which target viral DNA polymerase and provide broad coverage against HSV, VZV, and (at higher doses) CMV 4.
Patients with GVHD or frequent HSV reactivations before transplant require extended acyclovir prophylaxis beyond the standard duration 1. The decision to extend prophylaxis should be based on ongoing immunosuppression status, not on letermovir coverage.